Detailed Narrative
Q2 FY26 Performance Overview
Solara Active Pharma Sciences reported a challenging Q2 FY26 with revenue marginally declining 2% Q-o-Q to INR314 crores. The company's EBITDA saw a significant degrowth of 39% Q-o-Q, settling at INR35 crores, resulting in an 11% EBITDA margin. Despite these challenges, the gross margin profile remained healthy at 51%, with an absolute gross margin of INR160 crores, reflecting an 8% decline Q-o-Q.
Operational Challenges and FDA Audit Success
The Q2 performance was primarily impacted by short-term disruptions from an unscheduled operational shutdown of the Mangalore facility for upgradation, which lasted 3-4 weeks. This shutdown led to an estimated loss of INR30-35 crores in top line and INR18-20 crores at the gross margin level. However, a positive outcome of the upgradation was the successful clearance of a US FDA audit between August 25th and 29th, with only two minor procedural observations.
Financial Health and Debt Reduction Strategy
The company has made progress on debt reduction, decreasing it by approximately INR153 crores during H1 FY26, with INR113 crores from a rights issue and INR40 crores from operational cash. Management aims to reduce debt to INR446 crores by Q1 FY27, targeting a net debt-to-EBITDA ratio of 1.5x. The current cost of debt stands at 13%, which the company is actively exploring to reduce.
Gross Margin and Cost Structure
Solara maintained a healthy gross margin profile of 51% in Q2, though it dipped slightly from 54% in earlier quarters due to changes in product mix. Operating costs increased by INR9 crores Q-o-Q, primarily due to annual inflationary hikes in human resources and one-time📎 upgradation costs of INR4 crores for the Mangalore facility. Going forward⏳, the company expects its operating cost base to hover around INR117-120 crores.
Growth Outlook and New Product Pipeline
The company reiterated its FY26 outlook of 10% increment in sales and 15-20% EBITDA growth, with an aspirational EBITDA margin target of 20% by Q4 FY26. Management is focused on sustainable, scalable, and profitable growth, emphasizing making business choices to achieve target EBITDA levels rather than just top-line. New product development is a key growth engine, with a 2-3 year timeline for new products to reach the market, and efforts are underway to identify and develop these.
Liquidity and Working Capital Management
Management acknowledged that the current liquidity position is 'not very favorable,' with net current liabilities exceeding assets by over INR70 crores. The company is actively working to improve its Days Payable Outstanding (DPO) from the current 120-150 days to a target of 75-90 days within the next two quarters. This improvement is crucial for managing its working capital and overall financial health.